CoChat

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

Open access

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

An oligoclonal antibody overcomes drug resistance in colorectal cancers with EGFR mutations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aad5640

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Research works printed but not linked: 1

  1. Whitehead R. H., Macrae F. A., St. John D. J. B., Ma J., A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. J. Natl. Cancer Inst. 74, 759–765 (1985).

Cited by

See all 99

Metadata

Authors
Arena, S., Siravegna, G., Mussolin, B., Kearns, J. D., Wolf, B. B., Misale, S., Lazzari, L., Bertotti, A., Trusolino, L., Adjei, A. A., Montagut, C., Di Nicolantonio, F., Nering, R., & Bardelli, A.
Affiliations
  • IFOM (IT)
  • Candiolo Cancer Institute (IT)
  • Merrimack Pharmaceuticals (United States) (US)
  • Roswell Park Comprehensive Cancer Center (US)
  • Hospital Del Mar (ES)
  • Candiolo Cancer Institute–Fondazione del Piemonte per l'Oncologia (FPO), IRCCS, Candiolo, Torino 10060, Italy.
Corresponding author
  • Arena, Sabrina
  • Wolf, Beni B.
  • Misale, Sandra
  • Bardelli, Alberto
Venue
Science Translational Medicine
Published
2016-02-03
Volume
8
Issue
324
Pages
324ra14-324ra14
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W2265437850
Cited by
93
References
50
Citations by year
2026: 5 · 2025: 2 · 2024: 10 · 2023: 8 · 2022: 4 · 2021: 6 · 2020: 8 · 2019: 13 · 2018: 8 · 2017: 17 · 2016: 12
FWCI
8.98
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
  • Repositori digital de la UPF (Universitat Pompeu Fabra) (submittedVersion)
Funders
  • European Community's Seventh Framework Programme (602901 MErCuRIC, 635342-2 MoTriColor)
  • Innovative Medicines Initiative
  • Associazione Italiana per la Ricerca sul Cancro
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
cetuximab resistance, colorectal cancer, EGFR inhibition, circulating tumor DNA, RAS wild-type, EGFR signaling inhibition
MeSH terms
Cetuximab, Protein Domains, Panitumumab, Antibodies, Monoclonal, Epitopes, Cell-Free System, DNA, Neoplasm, Humans, Ligands, Mutation, Colorectal Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, HEK293 Cells, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. https://app.cochat.ai/papers/10.1126/scitranslmed.aad5640
The paper
Arena, S., Siravegna, G., Mussolin, B., Kearns, J. D., Wolf, B. B., Misale, S., Lazzari, L., Bertotti, A., Trusolino, L., Adjei, A. A., Montagut, C., Di Nicolantonio, F., Nering, R., & Bardelli, A. (2016). MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aad5640

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.